~~<i id='79B892AA8D'><strike id='79B892AA8D'><tt id='79B892AA8D'><pre id='79B892AA8D'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

fashion

author：explore 2025-09-06 04:51:34 - browse：6528

Alkermes shareholders voted Thursday to re-elect all of the drugmaker’s current directors, ending an acrimonious proxy fight with hedge fund Sarissa Capital Management, which had sought to seat three directors on the board.

At the company’s annual meeting, shareholders voted in favor of Alkermes’ proposal to retain all seven of the director nominees to the 11-person board.

The outcome is a setback for Sarissa, which owns 8.5% of Alkermes and is run by activist investor Alex Denner. Sarissa has accused Alkermes executives of mismanaging the business and destroying shareholder value.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Why are Kaiser Permanente staff considering a strike?

focus

hotspot

focus

knowledge

explore

AdobeThepressuresofthelastthreeandahalfyearshaveaffectedeverycornerofthehealthcarelandscape,butnowhe

WSS

Lasker Awards 2023: Winners in biomedical research

Senate HELP committee spars over health care workforce policies

Hearing on Medicare drug price negotiation gets unusually heated

FDA panel to weigh approval of NurOwn, controversial ALS drug

Biotech stock slump in 2023: awaiting the turnaround

Why scientists need input from humanists on sensitive research

explore

fashion

focus

DIEP, the 'gold standard' of breast reconstruction, is under threat

FDA advisers back CAR

Duchenne breakthrough therapy leaves behind pioneering families

Emergency workers more likely to restrain Black patients: study

BioMarin wins approval for gene therapy to treat hemophilia A

Readout Newsletter: Bristol, Sangamo, Gilead, and more

At least 13 dead in Texas as scorching temps continue

RaDonda Vaught links Vanderbilt hospital issues to patient death

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Readout Newsletter: Bristol, Sangamo, Gilead, and more

focus

Biotech lab space demand falls sharply

Microbiome research is starting to find links to chronic diseases

Thermo Fisher plant for manufacturing gene therapies to expand

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

CDC advisers recommend seasonal use of Pfizer RSV shot

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

hotspot

focus

knowledge

explore